Your browser is no longer supported. Please, upgrade your browser.
VCNX Vaccinex, Inc. daily Stock Chart
Vaccinex, Inc.
Index- P/E- EPS (ttm)-2.20 Insider Own4.00% Shs Outstand16.00M Perf Week-5.69%
Market Cap110.39M Forward P/E- EPS next Y-2.18 Insider Trans152.35% Shs Float13.01M Perf Month38.19%
Income-29.90M PEG- EPS next Q-0.51 Inst Own56.30% Short Float0.22% Perf Quarter59.20%
Sales0.40M P/S275.96 EPS this Y3.80% Inst Trans0.02% Short Ratio0.05 Perf Half Y-3.86%
Book/sh-1.61 P/B- EPS next Y-15.30% ROA-436.90% Target Price- Perf Year29.78%
Cash/sh- P/C- EPS next 5Y- ROE121.80% 52W Range3.22 - 12.23 Perf YTD23.09%
Dividend- P/FCF- EPS past 5Y- ROI122.20% 52W High-51.19% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin94.40% 52W Low85.40% ATR0.79
Employees45 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)50.90 Volatility9.63% 14.50%
OptionableNo Debt/Eq- EPS Q/Q43.50% Profit Margin- Rel Volume0.55 Prev Close6.45
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume532.33K Price5.97
Recom- SMA20-7.29% SMA5026.13% SMA20022.80% Volume292,479 Change-7.44%
Sep-04-18Initiated Ladenburg Thalmann Buy $22
Aug-05-20 12:30PM  
Jul-16-20 11:30AM  
Jul-07-20 08:37AM  
Jun-09-20 08:00AM  
May-14-20 10:05AM  
May-13-20 05:02PM  
Apr-27-20 07:45AM  
Apr-07-20 07:55AM  
Mar-31-20 07:55AM  
Mar-09-20 07:46AM  
Feb-06-20 07:31AM  
Dec-10-19 08:02AM  
Dec-09-19 07:55AM  
Nov-25-19 07:18PM  
Nov-14-19 07:55AM  
Nov-12-19 08:00AM  
Nov-09-19 08:02AM  
Oct-31-19 09:14AM  
Sep-27-19 06:05AM  
Sep-24-19 08:05AM  
Sep-06-19 10:45AM  
Aug-14-19 12:18PM  
Aug-13-19 08:05AM  
Aug-12-19 05:49PM  
Aug-02-19 01:41PM  
Aug-01-19 09:15AM  
Jul-31-19 07:30AM  
Jun-03-19 08:00AM  
May-15-19 08:10AM  
Apr-09-19 08:30AM  
Apr-01-19 08:00AM  
Mar-13-19 08:30AM  
Mar-06-19 08:30AM  
Jan-17-19 08:30AM  
Jan-16-19 08:30AM  
Dec-12-18 12:18PM  
Nov-27-18 07:30AM  
Nov-15-18 08:30AM  
Nov-13-18 07:58AM  
Nov-12-18 08:30AM  
Nov-06-18 08:30AM  
Oct-23-18 08:30AM  
Oct-02-18 08:30AM  
Sep-27-18 08:30AM  
Sep-25-18 08:30AM  
Sep-13-18 01:05PM  
Sep-04-18 11:12AM  
Aug-09-18 10:52AM  
Aug-05-18 09:48AM  
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leonard John E.SVP, DevelopmentJul 27Option Exercise3.901,0003,9001,000Jul 27 04:16 PM
FRIEDBERG ALBERTDirectorJul 10Buy3.551,126,7603,999,9981,710,093Jul 10 04:18 PM